In children with autism, following an anti-inflammatory diet for 12 weeks is linked to lower levels of specific inflammatory and metabolic markers in the blood, and these changes are associated with better performance in tasks involving verbal memory, attention, and visual-spatial reasoning.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether anti-inflammatory diets consistently produce coordinated reductions in CXCL1, RANTES, IFN-γ, and TMAO alongside cognitive improvements across multiple randomized trials in children with ASD.
A systematic review and meta-analysis of at least five high-quality RCTs (each n≥50) comparing structured anti-inflammatory diets to control diets in children aged 6–16 with confirmed ASD diagnosis, measuring pre-post changes in plasma CXCL1, RANTES, IFN-γ, TMAO, and standardized cognitive outcomes (WISC-IV, ENI-2) with blinded assessors, controlling for baseline biomarkers, diet adherence, and comorbidities.
Whether an anti-inflammatory diet directly causes reductions in CXCL1, RANTES, IFN-γ, and TMAO and subsequent improvements in verbal learning and attention in children with ASD, independent of placebo or caregiver effects.
A double-blind, placebo-controlled RCT with 100 children aged 6–16 with ASD, randomized to either a 12-week structured anti-inflammatory diet (NeuroGutPlus) or an isocaloric control diet with matched palatability and caregiver support, measuring plasma biomarkers and cognitive outcomes (WISC-IV, ENI-2) with blinded assessors, and using adherence monitoring via biomarkers (e.g., urinary metabolites).
Whether baseline levels of CXCL1, RANTES, IFN-γ, and TMAO predict the magnitude of cognitive improvement following an anti-inflammatory diet in children with ASD over time.
A prospective cohort study following 200 children with ASD over 24 months, measuring baseline and serial plasma biomarkers (CXCL1, RANTES, IFN-γ, TMAO) and cognitive performance every 3 months during dietary interventions, adjusting for confounders (sleep, activity, medication), to model predictive relationships between biomarker trajectories and cognitive change.
Whether children with ASD who respond to anti-inflammatory diets with cognitive gains have distinct baseline immunometabolic profiles compared to non-responders.
A case-control study comparing 50 ASD responders (≥0.5 SD cognitive improvement) to 50 non-responders matched for age, sex, and baseline cognition, analyzing pre-intervention plasma biomarkers, gut microbiota composition, and dietary intake patterns to identify predictive signatures.
Whether lower levels of CXCL1, RANTES, IFN-γ, and TMAO are associated with better cognitive performance in children with ASD at a single time point.
A cross-sectional analysis of 300 children with ASD, measuring plasma CXCL1, RANTES, IFN-γ, TMAO and standardized cognitive scores (WISC-IV, ENI-2) at one time point, adjusting for age, sex, socioeconomic status, and medication use, to assess cross-sectional associations.